Evidence map›Paper›PMID 33303244›Full record

ArticleEuropean urology2022

Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.

Kosj Yamoah, Shivanshu Awasthi, Brandon A Mahal, Shuang G Zhao, G Daniel Grass, Anders Berglund, Julieta Abraham-Miranda, Travis Gerke, Robert J Rounbehler, Elai Davicioni and 13 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 11 institutions in 2 countries.

Kosj YamoahH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Kosj.Yamoah@moffitt.org.
Shivanshu AwasthiH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Brandon A MahalUniversity of Miami Sylvester Comprehensive Cancer Center.
Shuang G ZhaoUniversity of Wisconsin, Department of Human Oncology.
G Daniel GrassH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Anders BerglundH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Julieta Abraham-MirandaH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Travis GerkeH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Robert J RounbehlerH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Elai DavicioniDecipher Bioscience, Vancouver, British Columbia, Canada.
Yang LiuDecipher Bioscience, Vancouver, British Columbia, Canada.
Jong ParkH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
John L ClevelandH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Julio M Pow-SangH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Daniel FernandezH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Javier Torres-RocaH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
R Jeffrey KarnesMayo Clinic, Rochester, MN, USA.
Edward SchaefferFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Stephen J FreedlandCedars-Sinai Medical Center, Los Angeles, CA, USA.
Daniel E SprattUniversity of Michigan, Ann Arbor, MI, USA.
Robert B DenThomas Jefferson University, Philadelphia, PA, USA.
Timothy R RebbeckDana Farber Cancer Institute, Boston, MA, USA.
Felix FengUniversity of California, San Francisco, CA, USA.
Moffitt Cancer Center · USDecipher Biosciences (Canada) · CACedars-Sinai Medical Center · USDana-Farber Cancer Institute · USMayo Clinic in Arizona · USNorthwestern University · USSylvester Comprehensive Cancer Center · USThomas Jefferson University · USUniversity of California, San Francisco · USUniversity of Michigan · USUniversity of Wisconsin–Madison · US

Funding

Precision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2018 to 2020
$3.2M
NCI NIH HHS P20 CA233255
6 · The paper itself

Abstract

Grade group 4 and 5 (GG-45) prostate cancer (PCa) patients are at the highest risk of lethal outcomes, yet lack genomic risk stratification for prognosis and treatment selection. Here, we assess whether transcriptomic interactions between tumor immune content score (ICS) and the Decipher genomic classifier can identify most lethal subsets of GG-45 PCa. We utilized whole transcriptome data from 8071 tumor tissue (6071 prostatectomy and 2000 treatment-naïve biopsy samples) to derive four immunogenomic subtypes using ICS and Decipher. When compared across all grade groups, GG-45 samples had the highest proportion of most aggressive subtype-ICS

Indexed as

Prostatic NeoplasmsTranscriptomeHumansMaleNeoplasm GradingProstateProstatectomyAggressive prostate cancerDecipher scoreGenomic riskGrade group 4Grade group 5High-grade prostate cancerImmune contentImmunogenomicsLethal outcomes

Identifiers

PMID33303244
PMCPMC9838823
OpenAlexW3110773361

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.